Close
Novotech
Jabsco PureFlo 21 Single Use

More Than 50% of Europe To Be Under The Clutches of Omicron

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Drug Manufacturing Deals Shift to Europe Despite Tariffs

Biopharma companies are continuing to redirect production strategies toward...

DeepCyte Raises $1.5M funding to Advance AI Drug Toxicology

DeepCyte, a techbio company focused on advancing AI Drug...

Hypercon Technology Deal Signed between Halozyme and Vertex

Halozyme Therapeutics has entered into a global exclusive partnership...
- Advertisement -

According to the forecast shared by WHO top officials more than half of Europe will suffer from the highly contagious variant of COVID-19, Omicron in the next couple of months. As per one of the top line directors at WHO, there is a sweep of the west to east tidal wave of infection of Omicron which in the region over and above the pre-existent delta variant.

The variant is dominantly stamping its spread across the west of Europe and is now charging towards the Balkans. The region has already seen above 7 million patients in the first week of this year. This figure is double to the two-week prior period. With the rate things are moving, the health metrics and evaluation institute predict that more than half of the regional population will be under the clutches of omicron and that too in the next 6-8 weeks.

The variant has swept the entire region at a brisk pace and countries, big or small, developed or developing are already introducing various social restrictions to curb its unwanted expanse. All the shreds of evidence however suggest that the omicron is less lethal than the delta variant but the sheer numbers are enough to overwhelm the health care system. One of the professors at Oxford believes that omicron is not the same virus as its predecessors and the horrific scenes that all had to go through of people succumbing prematurely, hospitals overflowing with admissions is history.

As far as the disease is concerned, the variant seems to be less impactful with many people being hospitalized for a less period of time. Oxygen high flow isn’t the need with an average stay of patients being three days max. The fact is that the places where COVID incident rates have been higher tagged with low vaccination turnouts, the mortality rate is stable.

Latest stories

Related stories

Drug Manufacturing Deals Shift to Europe Despite Tariffs

Biopharma companies are continuing to redirect production strategies toward...

DeepCyte Raises $1.5M funding to Advance AI Drug Toxicology

DeepCyte, a techbio company focused on advancing AI Drug...

Hypercon Technology Deal Signed between Halozyme and Vertex

Halozyme Therapeutics has entered into a global exclusive partnership...

Gilead Advances ADC Pipeline Expansion with $3B Tubulis Deal

Gilead Sciences has agreed to acquire Germany-based Tubulis in...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »